📰 Advanced Solid Tumors News
Page 6 - Advanced Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Advanced Solid Tumors. Real-time updates on events, politics, business and more.
March 23, 2023
- Cleared dose-limiting toxicity observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma cohort readout in 2H23 - Initiated the potentially... | March 23, 2023
March 1, 2023
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that...
February 8, 2023
- Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 -- Cabozantinib franchise achieved $1.40 billion in U.S. Net Product Revenues for the Full Year 2022, including $377.4 million for the Fourth Quarter 2022 -- GAAP Diluted EPS of $(0.09) for the Fourth Quarter of 2...
January 20, 2023
/PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of...
December 9, 2022
/PRNewswire/ -- Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced that...
November 29, 2022
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance...
November 29, 2022
-TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic- -Conference call and webcast today, Nov. 29th, at 9:00 am ET- CARLSBAD, Calif., Nov. 29, 2022 /PRNewswire/ -- Tyra...
November 4, 2022
Aberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma
November 2, 2022
– Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million – – GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 – – Conference Call... | November 1, 2022
November 2, 2022
Investegate announcements from Faron Pharma. Oy, Faron Announces Poster Presentation at SITC